Phosphodiesterase Type 5 Inhibitors for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
نویسندگان
چکیده
منابع مشابه
Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review.
OBJECTIVE • To review the evidence in support of the effectiveness of phosphodiesterase 5 inhibitors in lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). METHODS • Relevant studies were identified by performing a literature search using MEDLINE® and The Cochrane Library®. The criteria used during the search included randomized, placebo-controlled trials of trea...
متن کاملThe role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Phosphodiesterase type-5 (PDE-5) inhibitors are approved as the first line of therapy for the treatment of erectile dysfunction. However, different studies have been performed to study the use of these agents in other areas of urology. There are many studies related to the use of PDE-5 inhibitors as a monotherapy or combination therapy with alpha-blockers for lower urinary tract symptoms (LUTS)...
متن کاملBenign prostatic hyperplasia and lower urinary tract symptoms: research priorities.
Department of Urology, Sant’Andrea Hospital, University ‘‘La Sapienza,’’ Rome, Italy; Department of Urology, University Medical Centre HamburgEppendorf, Hamburg, Germany; Urology Clinic, Second University of Naples, Naples, Italy; Universitätsspital Basel, Urologische Klinik, Basel, Switzerland; Department of Urology, University Hospital of Lublin, Lublin, Poland; Department of Urology, Vita-Sa...
متن کاملTowards Better Treatment for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia?
1 INVITED EDITORIAL FOCUS: MS# F-125-2017 – Inhibition of smooth muscle contraction 2 and ARF 6 activity by the inhibitor for cytohesin GEFs, secinH3 in the human prostate 3 4 TOWARDS BETTER TREATMENT FOR LOWER URINARY TRACT SYMPTOMS 5 ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA? 6 7 Sabatino Ventura 8 Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 9 Pa...
متن کاملPhosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review
Many men have coexistent erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Phosphodiesterase type 5 (PDE5) inhibitors are effective for treating both of these conditions independently. In this review we summarise the evidence supporting a link between ED and LUTS/BPH, and the results from key clinical studies related to the use of P...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Urological Science
سال: 2010
ISSN: 1879-5226
DOI: 10.1016/s1879-5226(10)60002-4